Biopharmaceutical company Sage Therapeutics, Inc. (SAGE) and Biogen Inc.
Sage Therapeutics jumped almost 6% to close at $85.04 on Feb.
Sage Therapeutics (SAGE) has announced a massive restructuring that appears to abandon the launch of post-partum depression drug Zulresso. “Zulresso is a hospital-based …
If you really want to know which stocks the experts – and those in the know – are buying, pay attention to what …
The world’s population is getting older, rapidly. According to the United Nations, the fastest-growing age group across the world is adults aged 65 …
SAGE Therapeutics’ (SAGE) Zulresso, a post-partum depression drug – the first ever post-partum drug — is well along in its goal to become FDA …
Canaccord’s John Newman now sees almost 18% in upside potential for SAGE following a big clinical home run in major depressive disorder.
Experienced investors in search of growth know to look beyond current trends and market momentum or rely on pundit’s expectations. Today’s results are …
J.P.
A glimpse into three biotech movers: ALDX, SAGE, AEMD.